✦ LIBER ✦

One-Year Clinical Outcome of a Randomized Trial of Polymer-Free Paclitaxel-Eluting Stents Versus Biodegradable Polymer-Based Rapamycin-Eluting Stents in Patients with Coronary Heart Disease

✍ Scribed by LAN ZHANG; JIA YUAN; GAN LIU; JIN-PENG ZHONG; YUE-HUI YIN; QIANG SHE; LI SU; ZHI-YU LING; YUN-QING CHEN

Book ID: 109218151
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 498 KB
Volume: 25
Category: Article
ISSN: 0896-4327
DOI: 10.1111/j.1540-8183.2012.00722.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of a polymer-free rapamycin-e

Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions

✍ Johannes Ruef; Hans Störger; Franz Schwarz; Jürgen Haase, 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

Improved Late Clinical Safety With Zotar

Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial

✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB